CareDx to acquire Naveris for 260 million USD to expand precision medicine footprint into oncology

CareDx has agreed to acquire Naveris for an initial $160 million, plus $100 million in performance-based milestones. The move integrates Naveris’ liquid biopsy platform for HPV-driven cancers into CareDx’s specialty testing portfolio, targeting a high-growth segment of the molecular diagnostics market.

CareDx, a precision medicine firm specializing in transplant patient solutions, has entered a definitive agreement to acquire Naveris, a commercial-stage oncology diagnostics company. The deal includes an upfront cash payment of $160 million and up to $100 million in revenue-linked milestones. Naveris is known for its Tumor Tissue Modified Viral (TTMV) DNA platform, a blood-based monitoring tool for viral-mediated cancers such as head, neck, and anal malignancies. The transaction is expected to close in the third quarter of 2026.

This acquisition represents a significant strategic pivot for CareDx, leveraging its established reimbursement and clinical workflow infrastructure to enter the liquid biopsy and molecular residual disease (MRD) surveillance markets. Naveris reported $34 million in unaudited revenue for 2025 and is projected to maintain a 30% to 40% annual growth rate. By acquiring a platform that already secured Medicare coverage in 2023, CareDx mitigates regulatory risk while accessing a high-margin diagnostic vertical.

For the biotechnology and healthcare sectors, this consolidation highlights the increasing value of "tumor-naïve" testing technologies that simplify patient management from diagnosis through long-term surveillance. The deal impacts oncology providers and payers by potentially expanding access to high-accuracy biomarkers that outperform traditional imaging. For investors, the acquisition provides a diversified revenue stream beyond transplant services without negatively impacting CareDx's 2026 adjusted EBITDA guidance. Strategically, the integration of Naveris’ 65% gross margin business underscores a broader trend of specialty diagnostic firms seeking scale through the acquisition of reimbursed, high-growth molecular assets in concentrated clinical markets.